Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

ViroLogic Gets Molecular Cancer Test Platform With Aclara

This article was originally published in The Gray Sheet

  • News

Executive Summary

ViroLogic will leverage its established HIV resistance test infrastructure to commercialize Aclara's eTag molecular cancer assay platform under a $200 mil. definitive acquisition agreement, announced June 1

You may also be interested in...



J&J breast cancer test

Veridex unit will launch CellSearch metastatic breast cancer diagnostic system in the fall of 2004. During the American Society of Clinical Oncology meeting in New Orleans June 5, Johnson & Johnson explained that the CellSearch test - which identifies and counts circulating tumor cells in whole blood samples to predict progression-free and overall survival in metastatic breast cancer patients - should help physicians determine cancer treatment effectiveness much earlier than current methods, which can take up to three months. CellSearch will compete with products like ViroLogic's eTag molecular cancer assay in the burgeoning field of personalized medicine for oncology diseases (1"The Gray Sheet" June 7, 2004, p. 18)...

J&J breast cancer test

Veridex unit will launch CellSearch metastatic breast cancer diagnostic system in the fall of 2004. During the American Society of Clinical Oncology meeting in New Orleans June 5, Johnson & Johnson explained that the CellSearch test - which identifies and counts circulating tumor cells in whole blood samples to predict progression-free and overall survival in metastatic breast cancer patients - should help physicians determine cancer treatment effectiveness much earlier than current methods, which can take up to three months. CellSearch will compete with products like ViroLogic's eTag molecular cancer assay in the burgeoning field of personalized medicine for oncology diseases (1"The Gray Sheet" June 7, 2004, p. 18)...

Erbitux Companion Test Approval Clears Path For Further Co-Development

DakoCytomation expects reimbursement policies for ImClone's Erbitux colorectal cancer drug to guide adoption of companion diagnostic EGFR pharmDx

Table

View full table

Tags:
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT020370

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By